Gemcitabine and Docetaxel as Front-Line Chemotherapy in Patients with Carcinoma of an Unknown Primary Site

Cancer

Volumn 100, Issue 6, 2004, Pages 1257-1261

  Pouessel, Damien ^a   Culine, Stéphane ^a   Becht, Catherine ^a   Ychou, Marc ^a   Romieu, Gilles ^a   Fabbro, Michel ^a   Cupissol, Didier ^a   Pinguet, Frédéric ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Carcinoma of unknown primary site; Docetaxel; Gemcitabine; Response; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMA; CARCINOMA OF UNKNOWN PRIMARY SITE; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; EDEMA; FEMALE; HUMAN; MALE; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DEOXYCYTIDINE; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 1542314283     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20100     Document Type: Article

References (22)

1. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257-263.
2. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13:2094-2103.
3. Bugat R, Bataillard A, Lesimple T, et al. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003;89 (Suppl 1):S59-S66.
4. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679-4683.
5. Greco FA, Burris HA, Erland JB, et al. Carcinoma of unknown primary site. Cancer. 2000;89:2655-2660.
6. Greco FA, Erland JB, Morrisey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann:Oncol. 2000;11:211-215.
7. Briasoulis E, Kalofonos H, Bafaloukos, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol. 2000;18:3101-3107.
8. Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-1656.
9. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomised phase II study. Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479-3482.
10. Miller AB, Hoogstraten B, Staquet B, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
11. Johnson RO, Castro R, Ansfield FJ. Response of primary unknown cancers to treatment with 5-fluorouracil. Cancer Chemother Rep. 1964;68:63-64.
12. Moertel CG, Reitemeier RJ, Schutt AJ, Hahn RG. Treatment of the patient with adenocarcinoma of unknown origin. Cancer. 1972;30:1469-1472.
13. Fiore JJ, Kelsen DP, Gralla RJ, et al. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin. Cancer Treat Report. 1985;69:591-594.
14. Goldberg RM, Smith FP, Ueno W, et al. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol. 1986;4:395-399.
15. Milliken ST, Tattersall MHN, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site: a randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol. 1987;23:1645-1650.
16. Alberts AS, Falkson G, Falkson HC, et al. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol. 1989;17:188-192.
17. Kambhu SA, Kelsen DP, Fiore J, et al. Metastatic adenocarcinomas of unknown primary site. Am J Clin Oncol. 1990;13:55-60.
18. de Campos ES, Menasce LP, Radford J, et al. Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/EP). Cancer. 1994;73:470-475.
19. Falkson CI, Cohen GL. Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 1998;55:116-121.
20. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 1987;10:82-85.
21. Hainsworth JD, Burris HA, Calvert SW, et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 2001;19:335-339.
22. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003;23:2801-2804.